Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 10:52:39时区推断·⟳ 抓取 13:07:08回填·⚡ 决策 07-22 13:13:51·97.5 天前
Dyne Therapeutics以每股20.50美元公开发行1830万股，募资约3.7515亿美元
发行价20.50美元、发行1830万股、募资3.7515亿美元，较最新价23.83美元折价约14.0%，对现有股东有摊薄压力。
📄 原文Investing.com↗ 原文
Dyne Therapeutics prices $375 million stock offering
Nasdaq rises more than 1% as chip stocks extend rebound from bear market territory WALTHAM, Mass. - Dyne Therapeutics,…
不做 Dyne Therapeutics（DYN.US）
折价增发有摊薄利空，但消息已发布两天且股价反而上涨；未确认可借券数量，不能开空，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-20 · 扩散 medium · price-in 风险 high ↗
关键理由
- 发行价20.50美元、发行1830万股、募资3.7515亿美元，较最新价23.83美元折价约14.0%，对现有股东有摊薄压力。
- 但DYN.US最新价23.83美元、当日+1.62%，市场未按利空定价，且该融资可延长临床阶段公司现金 runway。
主要风险
- 公开增发利空与资金补强利好相互抵消；缺少可借券数量，不能满足做空执行红线。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-20 · 影响 weakens
融资对临床阶段公司也补充现金，且股价未按利空下跌，削弱做空胜率。
检索:Dyne Therapeutics offering use of proceeds cash runway bullish analyst 原文 ↗
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 1,680 字
Nasdaq rises more than 1% as chip stocks extend rebound from bear market territory
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN) announced Monday the pricing of an underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, according to a press release statement.
The clinical-stage company focused on neuromuscular diseases expects to receive gross proceeds of $375,150,000 before deducting underwriting discounts, commissions and offering expenses. All shares are being sold by Dyne.
The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. Dyne has granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, Jefferies and Evercore ISI are serving as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers, while Jones is serving as lead manager.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on March 5, 2024, which became automatically effective upon filing.
Dyne develops therapeutics targeting muscle and the central nervous system for genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, along with preclinical programs for facioscapulohumeral muscular dystrophy, Pompe disease and multiple DMD mutations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN) announced Monday the pricing of an underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, according to a press release statement.
The clinical-stage company focused on neuromuscular diseases expects to receive gross proceeds of $375,150,000 before deducting underwriting discounts, commissions and offering expenses. All shares are being sold by Dyne.
The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. Dyne has granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, Jefferies and Evercore ISI are serving as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers, while Jones is serving as lead manager.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on March 5, 2024, which became automatically effective upon filing.
Dyne develops therapeutics targeting muscle and the central nervous system for genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, along with preclinical programs for facioscapulohumeral muscular dystrophy, Pompe disease and multiple DMD mutations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。